Comparative analysis revealed that oral administration is more likely to induce gastrointestinal disorders such as pancreatitis, pancreatic cancer, belching, gastric emptying disorders, and gallstones when compared to subcutaneous injection
The treatment may support health benefits, including improved liver function, enhanced metabolism, and potential support for cardiovascular health [6]
Methods We evaluated available evidence by searching PubMed and EMBASE databases, according to specific inclusion and exclusion eligibility criteria to evaluate gastrointestinal adverse events associated with GLP-1 RAs in non-diabetic individuals with overweight or obesity
Sergey Terushkin, MD, FACS a top-rated bariatric and general surgeon trained at Ross University and fellowshiptrained in minimally invasive and bariatric surgery at Cleveland Clinic Florida